Comparative adjuvant trial evaluates Army-developed ALF in HIV vaccine regimens

(The U.S. Military HIV Research Program (MHRP)) A new Phase 1 vaccine study began today that will evaluate experimental prime/boost HIV-1 vaccine regimens formulated with combinations of different adjuvants, including one from the Army Liposome Formulation (ALF) family of adjuvants developed by scientists with the U.S. Military HIV Research Program (MHRP).